Synthetic cervical mucus formulation

Burruano, Bríd T.; Schnaare, Roger L.; Malamud, Daniel

doi:10.1016/s0010-7824(02)00336-0

Cited by 47 publications

(28 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antiviral activity of SAMTs in the presence of mucin and seminal plasma. To evaluate the effect of mucin on the activity of SAMT compounds, 0.5% pig mucin was solubilized in colorless complete RPMI as previously described (6). SAMTs were diluted 1:4 in the mucin-RPMI mixture and incubated for 2 h at 37°C.…”

Section: N-[2-(345-trimethoxybenzoylthio)benzoyl]-l-alaninamide (Samentioning

confidence: 99%

Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibitors Impede trans Infection in Cellular and Explant Models and Protect Nonhuman Primates from Infection

Wallace

Cheng‐Mayer

Schito

et al. 2009

J Virol

View full text Add to dashboard Cite

Here, we report that the S-acyl-2-mercaptobenzamide thioester (SAMT) class of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein (NCp7) inhibitors was able to prevent transmission of HIV-1 from infected cells, including primary cells. Furthermore, when SAMTs were introduced during an HIV-1 challenge of cervical explant tissue, inhibition of dissemination of infectious virus by cells emigrating from the tissue explants was observed. Preliminary studies using a rhesus macaque vaginal challenge model with mixed R5 and X4 simian-human immunodeficiency virus infection found that five of six monkeys were completely protected, with the remaining animal being partially protected, infected only by the R5 virus. These data suggest that SAMTs may be promising new drug candidates for further development in anti-HIV-1 topical microbicide applications.

show abstract

Section: N-[2-(345-trimethoxybenzoylthio)benzoyl]-l-alaninamide (Samentioning

confidence: 99%

Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibitors Impede trans Infection in Cellular and Explant Models and Protect Nonhuman Primates from Infection

Wallace

Cheng‐Mayer

Schito

et al. 2009

J Virol

View full text Add to dashboard Cite

show abstract

“…The systems were evaluated in terms of the thermal behavior and the viability of their use as delivery systems. In other study, Burruano et al [18] evaluated the cross-linking of GG with sodium borate solution and reported that the process was efficient in terms of reducing the solubility. Also, Chaurasia et al [19] prepared cross-linked guar gum microspheres using glutaraldehyde as a crosslinking agent.…”

Section: Introductionmentioning

confidence: 99%

Preparation, Characterization and Properties of Films Obtained from Cross-linked Guar Gum

Banegas¹,

Zornio²,

Borges³

et al. 2013

Polímeros

View full text Add to dashboard Cite

Abstract:In this study the viability of using guar gum to form films was investigated along with the effectiveness of the cross-linking process employing 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) as the cross-linking agent. In addition, the cross-linked films were evaluated considering the water absorption, thermal stability and mechanical properties. The cross-linking process of guar gum films was confirmed by the low solubility in water and through infrared analysis. The results shown that the properties evaluated were affected by the cross-linking process due to changes in the polysaccharide structure. For example, the swelling behavior and water vapor absorption decreased with an increase in the amount of EDC. The EDC content (10-30%) also affected the polymer structure and hydrogen bond formation, reducing the thermal stability of the system.

show abstract

“…It has been demonstrated that the rheological properties of native mucus cannot be mimicked by even very concentrated gastric commercial mucin solutions [32]. Consequently, different simulated mucus mixtures have been developed to have a rheological profile corresponding to native mucus from, for example the small intestine [14] and the cervix [33] or without considerations to rheology, but with focus on in vivo-like composition [34]. A thorough characterization of such mixtures is necessary to justify the relevance and reproducibility of their intended use.…”

Section: Mimicking the Mucus Barriermentioning

confidence: 99%

Mucus as a Barrier to Drug Delivery – Understanding and Mimicking the Barrier Properties

Boegh

Nielsen

2014

Basic Clin Pharma Tox

273

185

View full text Add to dashboard Cite

Viscoelastic mucus lines all mucosal surfaces of the body and forms a potential barrier to mucosal drug delivery. Mucus is mainly composed of water and mucins; high molecular weight glycoproteins forming an entangled network. Consequently, mucus forms a steric barrier, and due to its negative charge and hydrophobic domains, the overall hydrophilic mucus also presents an interactive barrier limiting the free diffusion of components within and through the mucus. Furthermore, mucus is a dynamic barrier due to its continuous secretion and shedding from the mucosal surfaces. Mucus is thus a highly complex gel barrier to drug delivery. Current knowledge of mucus characteristics and barrier properties, as achieved by state-of-the-art methodologies, is the topic of this MiniReview emphasizing the gastrointestinal mucus and an overall focus on oral drug delivery. Cell culture-based in vitro models are well-established as essential tools in drug research and development, but traditionally, mucus-containing models have only rarely been applied. However, a number of mucus-containing in vitro models have recently been described in the literature, and their properties and applications will be reviewed and discussed. Finally, studies of peptide and protein drug diffusion in and through mucus and studies of mucus-penetrating nanoparticles are included to illustrate the mucus as a potentially important barrier to obtain sufficient bioavailability of orally administered drugs, and thus an important parameter to address in the development of future oral drug delivery systems.

show abstract

Synthetic cervical mucus formulation

Cited by 47 publications

References 8 publications

Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibitors Impede trans Infection in Cellular and Explant Models and Protect Nonhuman Primates from Infection

Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibitors Impede trans Infection in Cellular and Explant Models and Protect Nonhuman Primates from Infection

Preparation, Characterization and Properties of Films Obtained from Cross-linked Guar Gum

Mucus as a Barrier to Drug Delivery – Understanding and Mimicking the Barrier Properties

Contact Info

Product

Resources

About